drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive T-cell therapy)
drug_description
Autologous ex vivo-expanded T cells isolated from the patient’s tumor, infused to provide tumor-specific cytotoxic CD8+/CD4+ T cells for adoptive cellular immunotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-resident T cells isolated from the patient’s tumor are expanded ex vivo and reinfused to provide polyclonal, tumor‑antigen–specific CD8+/CD4+ T cells. These cells recognize tumor antigens via their native TCRs in an MHC-restricted manner and mediate cytotoxicity (perforin/granzyme) and cytokine release to eliminate tumor cells; they are not genetically engineered.
drug_name
Tumor-Infiltrating Lymphocytes (TIL)
nct_id_drug_ref
NCT06532812